Targeted Mass Spectrometry Enables Multiplexed Quantification of Immunomodulatory Proteins in Clinical Biospecimens.
Targeted Mass Spectrometry Enables Multiplexed Quantification of Immunomodulatory Proteins in Clinical Biospecimens.
复制标题
DOI:
10.3389/fimmu.2021.765898
复制
发表时间:
2021
影响因子:
7.3
通讯作者:
Paulovich AG
中科院分区:
文献类型:
--
作者:
Whiteaker JR;Lundeen RA;Zhao L;Schoenherr RM;Burian A;Huang D;Voytovich U;Wang T;Kennedy JJ;Ivey RG;Lin C;Murillo OD;Lorentzen TD;Thiagarajan M;Colantonio S;Caceres TW;Roberts RR;Knotts JG;Reading JJ;Kaczmarczyk JA;Richardson CW;Garcia-Buntley SS;Bocik W;Hewitt SM;Murray KE;Do N;Brophy M;Wilz SW;Yu H;Ajjarapu S;Boja E;Hiltke T;Rodriguez H;Paulovich AG
Immunotherapies are revolutionizing cancer care, producing durable responses and potentially cures in a subset of patients. However, response rates are low for most tumors, grade 3/4 toxicities are not uncommon, and our current understanding of tumor immunobiology is incomplete. While hundreds of immunomodulatory proteins in the tumor microenvironment shape the anti-tumor response, few of them can be reliably quantified. To address this need, we developed a multiplex panel of targeted proteomic assays targeting 52 peptides representing 46 proteins using peptide immunoaffinity enrichment coupled to multiple reaction monitoring-mass spectrometry. We validated the assays in tissue and plasma matrices, where performance figures of merit showed over 3 orders of dynamic range and median inter-day CVs of 5.2% (tissue) and 21% (plasma). A feasibility study in clinical biospecimens showed detection of 48/52 peptides in frozen tissue and 38/52 peptides in plasma. The assays are publicly available as a resource for the research community.
影响因子:
9.3
作者:
Schoenherr RM;Voytovich UJ;Whiteaker JR;Gadi VK;Gralow JR;Paulovich AG
通讯作者:
Paulovich AG